Home
    • Plans Blog Contact
    MYOMO, INC. logo

    MYOMO, INC.

    MYO
    Last price US$0.99
    Market cap US$42.6m
    12M price change -53.95%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Abbott LaboratoriesABT Industry peer DexCom IncDXCM Industry peer Edwards Lifesciences CorpEW Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    MYOMO, INC. Overview

    Industry: Medical Devices

    Sector: Healthcare

    Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, China, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, rehabilitation hospitals and surgery centers, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts. Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, China, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for MYOMO, INC. into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 07, 2026

    Quarterly result summary

    Revenue was $10.1M (reported). Net loss was -$3M. Adjusted EBITDA was -$2.3M (-20% YoY).

    Revenue $10.1M reported
    Net loss -$3M reported
    Adjusted EBITDA -$2.3M -20% YoY
    Cash $15.7M reported

    What changed

    • Revenue reported to $10.1M.
    • Adjusted EBITDA -20% YoY to -$2.3M.

    Guidance / outlook

    we expect to grow revenue sequentially with modestly higher operating expenses from increased advertising spend as changes made in our marketing program continue to gain traction," added Mr.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q May 07, 2026 SEC filing 8-K May 07, 2026 SEC filing 10-K/A Apr 29, 2026 SEC filing 10-K Mar 09, 2026 SEC filing 8-K Mar 09, 2026 Earnings release Earnings release Mar 09, 2026 SEC filing 10-Q Nov 10, 2025 Earnings release Earnings release Nov 10, 2025 SEC filing 8-K Aug 11, 2025 Earnings material Earnings release Aug 11, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 5.00/5
    MYOMO, INC. boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Medical Devices industry , Abbott Laboratories , DexCom Inc , Edwards Lifesciences Corp are companies with high ratings.

    Return on Equity

    Score 0.53/5
    MYOMO, INC. exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    MYOMO, INC. MYO US$42.6m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 1.67/5
    MYOMO, INC. olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    MYOMO, INC. MYO US$42.6m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Medical Devices industry , Abbott Laboratories , DexCom Inc , Edwards Lifesciences Corp are companies with high ratings.

    Leverage

    Score 2.45/5
    MYOMO, INC. registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    MYOMO, INC. MYO US$42.6m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    MYOMO, INC. logo

    MYOMO, INC.

    US$0.99

    US$42.6m

    3.87%

    -53.95%